CIA
BMRN icon

Caerus Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Caerus Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$233K Sell
4,073
-832
-17% -$45.6K 0.08% 270
2026
Q1 		$277K Sell
4,905
-5,331
-52% -$311K 0.12% 187
2025
Q4 		$608K Buy
10,236
+278
+3% +$15.1K 0.2% 115
2025
Q3 		$539K Buy
+9,958
New +$569K 0.22% 105

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Caerus Investment Advisors's BMRN Position: Q2 2026 in Review

Caerus Investment Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 17% in Q2 2026, selling an estimated $45.6K and leaving 4,073 shares worth $233K. The position accounts for 0.08% of the portfolio, ranked #270.

Caerus Investment Advisors first reported a position in BMRN in Q3 2025 and has held it in 4 quarters since. The position peaked at $608K in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Caerus Investment Advisors held 4,073 shares of BioMarin Pharmaceuticals worth $233K as of Q2 2026.
  • Caerus Investment Advisors sold 832 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $45.6K.
  • BioMarin Pharmaceuticals made up 0.08% of Caerus Investment Advisors's portfolio in Q2 2026, its #270 holding.
  • Caerus Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Caerus Investment Advisors's BioMarin Pharmaceuticals position peaked at $608K in Q4 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Caerus Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.